The Theranostics Market was valued at $3.60 Billion in 2025 and is projected to reach $12.01 Billion by 2035, growing at a CAGR of 12.8 percent over 2026 to 2035, according to Strategic Revenue Insights. Radioligand therapy approvals are the largest growth driver, adding about 4.0 percentage points a year as targeted radiotherapies move from trials into routine oncology practice.
Click here for free sample PDF: https://www.strategicrevenueinsights.com/industry/theranostics-market
Theranostics Market Key Takeaways
- Market size rises from $3.60 Billion in 2025 to $12.01 Billion by 2035, passing $6.57 Billion in 2030.
- Oncology is the largest application at 79.00 percent share and grows at a 13.2 percent CAGR.
- Lutetium-177 leads radioisotopes at 38.00 percent, while Actinium-225 grows fastest at 23.0 percent CAGR.
- North America holds 45.00 percent of 2025 revenue, and Asia Pacific is the fastest-growing region at 15.7 percent CAGR.
- Novartis leads the competitive field with an estimated 17.0 percent share.
What Is Driving Growth
Three forces are pushing the market forward. Radioligand therapy approvals contribute about 4.0 percentage points a year to growth as new targeted radiotherapies gain regulatory clearance and reimbursement. Precision oncology adds about 3.2 points, with molecular imaging increasingly used to select patients and confirm treatment response. Alpha emitter development adds a further 2.4 points as next-generation isotopes such as Actinium-225 progress through clinical programs. On the other side, isotope supply limits subtract about 2.0 points and constrained nuclear medicine capacity subtracts 1.2 points, which keeps supply chain investment at the center of the industry’s agenda.
Segments, Regions and Key Players
By application, oncology dominates at 79.00 percent share and grows at a 13.2 percent CAGR, while endocrinology is the fastest non-oncology use at 12.0 percent. Radiotheranostics is the largest modality at 58.00 percent, and nanoparticle-based approaches are the fastest-growing at 15.0 percent. Among radioisotopes, Lutetium-177 holds 38.00 percent and Actinium-225 grows fastest at a 23.0 percent CAGR. Hospitals are the largest end user at 62.00 percent with a 12.5 percent CAGR, while specialty clinics grow fastest at 14.2 percent.
North America is the largest region at 45.00 percent share, worth $1.62 Billion in 2025, and grows at 11.4 percent. Asia Pacific is the fastest-growing region at a 15.7 percent CAGR. Key players include Novartis at 17.0 percent, Lantheus at 9.0 percent, Telix Pharmaceuticals at 7.5 percent, Curium at 7.0 percent, Bayer at 5.0 percent, Eli Lilly at 4.5 percent and GE HealthCare at 4.0 percent. The full report (ID 92120, 201 pages) covers the complete segment, regional and company analysis.
Frequently Asked Questions
How big is the Theranostics Market?
The market was valued at $3.60 Billion in 2025 and is projected to reach $12.01 Billion by 2035, growing at a 12.8 percent CAGR from 2026 to 2035.
Which segment leads the Theranostics Market?
Oncology is the largest application at 79.00 percent share. By modality, radiotheranostics leads at 58.00 percent, and Lutetium-177 is the largest radioisotope at 38.00 percent.
Which region is growing fastest?
Asia Pacific is the fastest-growing region at a 15.7 percent CAGR, while North America remains the largest region with a 45.00 percent share in 2025.
About Strategic Revenue Insights Inc.
Strategic Revenue Insights Inc., a subsidiary of SRI Consulting Group Ltd headquartered in London, provides syndicated market research reports, consulting and strategic insights. Contact: sales@strategicrevenueinsights.com | www.strategicrevenueinsights.com